Regulation of peripheral vascular tone in patients with heart failure: Contribution of angiotensin II

Heart

Volumn 80, Issue 2, 1998, Pages 134-141

  Newby, D E ^a   Goodfield, N E R ^b   Flapan, A D ^a   Boon, N A ^a   Fox, K A A ^a   Webb, D J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b STOBHILL HOSPITAL   (United Kingdom)

Author keywords

Angiotensin II; Heart failure; Peripheral vascular tone; Sympathetic nervous system

Indexed keywords

ANGIOTENSIN; ENDOTHELIN 1; LOSARTAN; NORADRENALIN;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTERY CONSTRICTION; ARTERY TONE; ARTICLE; BLOOD FLOW; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0031844672     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.80.2.134     Document Type: Article

References (40)

1. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346:1403-7.
2. Brough RB, Cowley AW, Guyton AC. Quantitative analysis of the acute response to hemorrhage of the reninangiotensin-vasoconstrictor feedback loop in areflexic dogs. Cardiovasc Res 1975;9:722-33.
3. Seidelin PH, Collier JG, Struthers AD, et al. Angiotensin II augments sympathetically mediated arteriolar constriction in man. Clin Sci 1991;81:261-6.
4. Cockcroft JR, O'Kane KPJ, Webb DJ. Tissue angiotensin generation and regulation of vascular tone. Pharmacol Ther 1995;65:193-213.
5. Hjemdahl P, Friberg P. Biochemical assessment of sympathetic activity and prejunctional modulation of noradrenaline release in humans. J Hypertens 1996;14:147-50.
6. Levine TB, Olivari MT, Garberg V, et al. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. Circulation 1984;69:548-53.
7. Creager MA, Massie BM, Faxon DP, et al. Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. J Am Coll Cardiol 1985;6:163-73.
8. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-32.
9. Cohn JN, Johnson G, Zeische S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
10. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
11. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
12. Drexler H, Kurz S, Jeserich M, et al. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol 1995;76:13-18E.
13. Crozicr I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995;91: 691-7.
14. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-9.
15. Webb DJ. The pharmacology of human blood vessels in vivo. J Vase Res 1995;32:2-15.
16. Benjamin N, Calver A, Collier J, et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995;25:918-23.
17. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone in man. Lancet 1994;344:852-4.
18. Vallance P, Collier J, Moncada S. Effects of endotheliumderived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;ii:997-1000.
19. Webb DJ. Sympathetic vasoconstriction and local converting enzyme activity within the upper limb circulation in man: studies with particular relevance to the action of angiotensin. London: University of London, 1990. (MD thesis.)
20. Taddei S, Virdis A, Mattei P, et al. Angiotensin II and sympathetic activity in sodium-restricted essential hypertension. Hypertension 1995;25:595-601.
21. Baan J, Chang PC, Vermeij P, et al. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed. Cardtovasc Res 1996;32:973-9.
22. Newby DE, Masumori S, Johnston NR, et al. Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man. Cardiovasc Res 1997;36:268-75.
23. Wiinberg N, Walter-Larson S, Eriksen C, et al. An evaluation of semi-automatic blood pressure manometers against intra-arterial blood pressure. Journal of Ambulatory Monitoring 1988;1:303-9.
24. Rolinski B, Bogner SJ, Goebel FD. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med 1994;194:9-24.
25. Morton JJ, Webb DJ. Measurement of plasma angiotensin II. Clin Sci 1985;68:483-4.
26. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
27. Goldstein DS, Feuerstein G, Izzo JL, et al. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci 1981;28:467-75.
28. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-45.
29. Cohn JC, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986;314:1547-52.
30. Groves P, Kurz S, Just H, et al. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995;92:3424-30.
31. Pin B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997;349:747-52.
32. Levine TB, Francis GS, Goldsmith SR, et al. The neurohumoral and hemodynamic response to orthostatic tilt in patients with congestive heart failure. Circulation 1983;67: 1070-5.
33. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation 1984;69:451-60.
34. Nishian K, Kawashima S, Iwasaki T. Paradoxical forearm vasodilatation and haemodynamic improvement during cardiopulmonary baroreceptor unloading in patients with congestive heart failure. Clin Sci 1993;84:271-80.
35. Leimbach WN, Wallin BG, Victor RG, et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913-19.
36. Levine TB, Francis GS, Goldsmith SR, et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-66.
37. Kluger J, Cody R, Laragh J. The contribution of sympathetic tone and the renin-angiotensin system to severe congestive heart failure: response to specific inhibitors (prazosin and captopril). Am J Cardiol 1982;49:1667-72.
38. Clemson B, Gaul L, Gubin SS, et al. Prejunctional angiotensin II receptors. J Clin Invest 1994;93:684-91.
39. Goldsmith SR, Rector TS, Bank AJ, et al. Effect of angiotensin II on noradrenaline release in the human forearm. Cardiovasc Res 1994;26:663-6.
40. MacGregor GA. Dietary sodium and blood pressure [letter]. Lancet 1994;343:545-6.